

Apollomics expands leadership team with appointment of Dr Jane Wang as CSO

July 26, 2022 | News

Dr Wang will lead the drug discovery pipeline for the Company



China's Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, has announced the appointment of Dr Jane Wang, as Chief Scientific Officer (CSO). In this role, Dr Wang will lead the drug discovery pipeline for the company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer.

Dr Wang brings over 20 years of drug discovery experience in the biopharmaceutical industry. Most recently, she served as Vice President, Medicinal Chemistry at WuXi AppTec where she worked to enhance RNA drug discovery and led multiple teams in medicinal chemistry and synthetic organic chemistry.

Prior to WuXi, Dr Wang spent 12 years on the drug discovery team at Pfizer, Inc. as a senior principal scientist, focusing on diseases in oncology, inflammation, and the central nervous system. Previously, she did her postdoc at the U.S. National Institute of Health and at Schering-Plough. Dr Wang earned a Ph.D. from the University of Maryland Baltimore County and a B.S. in Applied Chemistry from Fudan University. She is an inventor/co-inventor of over 50 patent applications and an author of over 35 publications.